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Background: Resistance to thyroid hormone alpha (RTHa), a disorder characterized by tissue-selective hy-
pothyroidism and near-normal thyroid function tests due to thyroid receptor alpha gene mutations, is rare but
probably under-recognized. This study sought to correlate the clinical characteristics and response to thyroxine
(T4) therapy in two adolescent RTHa patients with the properties of the THRA mutation, affecting both TRa1
and TRa2 proteins, they harbored.
Methods: Clinical, auxological, biochemical, and physiological parameters were assessed in each patient at
baseline and after T4 therapy.
Results: Heterozygous THRA mutations occurring de novo were identified in a 17-year-old male (patient
P1; c.788C>T, p.A263V mutation) investigated for mild pubertal delay and in a 15-year-old male (patient
P2; c.821T>C, p.L274P mutation) with short stature (0.4th centile), skeletal dysplasia, dysmorphic facies,
andglobaldevelopmental delay.Both individuals exhibitedmacrocephaly, delayeddentition, andconstipation, together
with a subnormalT4/triiodothyronine (T3) ratio, low reverseT3 levels, andmild anemia.When studied in vitro, A263V
mutant TRa1was transcriptionally impaired and inhibited the function of itswild-type counterpart at low (0.01–10nM)
T3 levels, with higher T3 concentrations (100 nM–1lM) reversing dysfunction and such dominant negative inhibition.
In contrast, L274P mutant TRa1 was transcriptionally inert, exerting significant dominant negative activity, only
overcomewith 10lMof T3.Mirroring this, normal expression of KLF9, a TH-responsive target gene, was achieved in
A263V mutation-containing peripheral blood mononuclear cells following 1lM of T3 exposure, but with markedly
reduced expression levels in L274P mutation-containing peripheral blood mononuclear cells, even with 10lM of T3.
Following T4 therapy, growth, body composition, dyspraxia, and constipation improved in P1, whereas growth
retardation and constipation in P2 were unchanged. Neither A263V nor L274P mutations exhibited gain or loss of
function in the TRa2 background, and no additional phenotype attributable to this was discerned.
Conclusions:This study correlates amilder clinical phenotype and favorable response to T4 therapy in a RTHa patient
(P1) with heterozygosity for mutant TRa1 exhibiting partial, T3-reversible, loss of function. In contrast, a more severe
clinical phenotype refractory to hormone therapy was evident in another case (P2) associated with severe, virtually
irreversible, dysfunction of mutant TRa1.
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Introduction
Resistance to thyroid hormone alpha (RTHa), adisorder characterized by tissue-selective features of
hypothyroidism due to defective thyroid receptor alpha, has
eluded recognition probably because it is associated with near-
normal thyroid function tests. Thirteen different THRA muta-
tions in 19 cases from 14 families have been recorded hitherto
(1–9): nine mutations, selectively involving the divergent car-
boxyterminal domain of thyroid hormone receptor a1 (TRa1),
are generally more deleterious exhibiting severe loss of func-
tion; four missense mutations are associated with variably
impaired function of TRa1, with higher concentrations of tri-
iodothyronine (T3) reversing mutant receptor dysfunction both
in vitro (8,9) and in mutation-containing patient-derived cells
studied ex vivo (6). These missense mutations also involve the
non-TH binding TRa2 protein, with no discernible gain or loss
of function or added phenotypes attributable to mutant a2 in
virtually all cases (6,8,9), except a single patient who exhibited
a constellation of unusual anomalies (7).
While the identification of a number of RTHa cases has
enabled key features of the disorder to be elucidated (10),
how these characteristics are linked to the underlying
THRA defect is ill-defined. Likewise, whether there is any
relationship between the degree and reversibility of mu-
tant TRa1 dysfunction in vitro and patient’s response to
thyroxine (T4) therapy is unclear. This article describes
two adolescent males with de novo missense mutations
(A263V and L274P) involving both TRa1 and a2 proteins.
The divergent functional properties of these mutants, with
lesser severity and greater reversibility of A263V mutant
receptor dysfunction compared to L274P TRa1, correlates
with differences in clinical characteristics of patients har-
boring the respective receptor defects and their responses
to T4 therapy.
Patients and Methods
Case descriptions
Patient P1. P1 was the second child of healthy parents
with one older sibling. Labor was induced at 39+ 4 weeks
gestation due to large fetal size (birth weight 4.58 kg, 98th
centile) and parturition complicated by shoulder dystocia. A
small umbilical hernia was noted in the early postnatal period.
The patient was breastfed for three months; weight was on the
98th centile from birth to at least two years of age, with length
initially on the 91st centile (56.5 cm) but falling to the 9th
centile (87 cm) at two and a half years. Bilateral inguinal hernia
repair was performed in infancy (4 months and 10 months).
At eight months, maternal concern that he was excessively
‘‘placid’’ and with slow movements was supported by evi-
dence of mild developmental delay. He only sat indepen-
dently at eight months, walked at 24 months, and did not
speak until after two years of age. In childhood, inability to
use stairs, hop, use a ball, tie shoelaces (until 11 years of age),
and cycle (until 12 years age of age, requiring specific tuition
for this) suggested problems with coordination. Objective
assessment (at nine years of age) confirmed poor motor skills
(<5th centile for age) and an unspecified developmental co-
ordination disorder for which he received occupational
therapy. Several persistent deciduous teeth (removed at 15
years of age) indicated delayed dentition.
Referral to a pediatrician for possible delayed puberty at 16
years of age (although he was in mid-puberty G4P3, testicular
volume 20mL, when assessed) documented an unusual pattern
of thyroid function tests (thyrotropin [TSH] 3.20mIU/L [refer-
ence range 0.27–4.20mIU/L], free T4 [fT4] 9.0 pmol/L [refer-
ence range 12–22pmol/L], free T3 [fT3] 8.0 pmol/L [reference
range 3.9–6.7 pmol/L]), prompting further investigation. With a
little teaching support, he has completed secondary-level edu-
cation and is currently enrolled at university.
Patient P2. P2 is the fourth child of healthy parents and
siblings. Following a normal pregnancy, labor was induced at
41+ 5 weeks. He weighed 3.26 kg (9th centile), and coronal
hypospadias and umbilical hernia was noted. Failure to thrive
in the first six months of infancy (weight <0.4th centile) ne-
cessitated energy-dense formula feeding. Developmental de-
lay, first noted at nine weeks, persisted throughout childhood.
He first sat at 12 months, pulled himself to stand at 22 months,
and walked at two and a half years. Formal assessment at two
and a half years of age showed delayed gross motor skills (at
12-month level) and significant speech delay (only two-word
vocabulary). Other notable features included dysmorphic fa-
cies, truncal hypotonia, delayed dentition (first tooth eruption
at two years of age), myopic astigmatism, genu valgum, an-
kyloglossia, skeletal dysplasia (Wormian bones, short tubular
hand bones, delayed closure of the anterior fontanelle, coxa
valga, femoral epiphyseal dysgenesis, mesomelic shortening
of upper and lower limbs, delayed bone age [bone age one year
and three months at chronological age three years and three
months]), bilateral hydroceles, and constipation. Abnormal
thyroid function tests presumed indicative of central hypo-
thyroidism (TSH 2.4mIU/L [reference range 0.4–5.5mIU/L],
fT4 9.0 pmol/L [reference range 10–18.7 pmol/L]) at 11 years
of age prompted commencement of T4 treatment. Subsequent
pubertal development was normal. He attends a school for
children with special needs and has persistent learning dis-
ability. Abnormal thyroid function and global developmental
delay prompted further investigation at 15 years of age.
Methods
All investigations were undertaken either as part of a
protocol approved by a local Research Ethics Committee
(Cambridgeshire, LREC 98/154) and/or were clinically in-
dicated and undertaken with prior written informed consent
of patients and/or parents.
Biochemical measurements
Thyroid function tests (fT4, fT3, TSH, reverse T3 [rT3])
and biochemical measurements (creatine kinase [CK], sex
hormone binding globulin, IGF1, lipids, hematocrit) were
assayed, as described previously (6).
Resting energy expenditure and body composition
Resting energy expenditure (REE) was measured by indi-
rect calorimetry using a ventilated canopy (GEM; GEMNu-
trition, Daresbury, United Kingdom) and body composition
using dual energy X-ray densitometry (DEXA; Encore;
GE Medical Systems, Madison, WI). The coefficient of vari-
ation for repeated REE measurement in subjects is +4%
(0.24MJ/day).
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Molecular genetic studies
Coding exons of the THRA gene were polymerase chain
reaction (PCR) amplified from genomic DNA using specific
primers and analyzed by Sanger sequencing, as described
previously (1).
Construction of wild-type, A263V, or L274P mutant
TRa and other vectors
Receptor mutations were generated by site directed mu-
tagenesis of wild-type (WT) human TRa1 or TRa2 cDNAs,
and cloned into a eukaryotic expression vector (pcDNA3),
downstream of a Flag epitope tag. Full lengthWT and mutant
TRa1 cDNAs were cloned in pCMX-VP16 (kind gift from R.
Evans) to yield VP16-TRa1 fusions. Constructs expressing
the Gal4DBD alone or fused to receptor-interacting domains
of NCoR and TRAP220 and reporter genes containing a
thyroid response element (MALTKLUC) or GAL4 binding
site (UASTKLUC) have been described previously (6).
Electrophoretic mobility shift assays
32P-labeled probes of a direct repeat thyroid response el-
ement from the malic enzyme gene were incubated with
in vitro translated WT and mutant TRa1 proteins with or
without RXR and 100 nM of T3 and analyzed by gel elec-
trophoresis, as described previously (6).
Transfection assays and Western blotting
For transcriptional activity and dominant negative inhibi-
tion assays, JEG-3 cells, cultured in 96-well plates with
OptiMEM/10% stripped fetal calf serum, were cotransfected
with MALTKLUC, TR expression vectors, and a plasmid
(Bos-b-gal) to monitor transfection efficiency, assaying lu-
ciferase and beta-galactosidase activity at 36 hours following
T3 exposure, as reported previously (6). Data shown are
normalized to maximal reporter gene activation with WT
receptor and represent the mean and standard error of the
mean (SEM) of at least five independent experiments, each
performed in triplicate. In two hybrid assays, JEG-3 cells
were cotransfected with UASTKLUC, Gal4DBD- and VP16-
TR fusion constructs, and Bos-b-gal, assaying luciferase and
beta-galactosidase activity as above. Values shown are ex-
pressed as a percentage of the WT maximum response and
are the mean and SEM of at least five independent experi-
ments each undertaken in triplicate. Western blotting of JEG-
3 cell lysates using Flag (F3165; Sigma–Aldrich, St. Louis,
MO) and VP16 (sc-7545; Santa Cruz Biotechnology, Dallas,
TX) antibodies quantitated TR and VP16 fusion proteins,
respectively, with beta-actin levels verifying comparable
protein input.
Quantitative real-time PCR analysis
of gene expression
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll gradient centrifugation and cultured for 24 h in
RPMI/5% stripped fetal bovine serum in the presence of in-
creasing concentrations of T3. RNA, isolated using a RNeasy
Mini Kit (Qiagen, Hilden, Germany) was reverse transcribed
and analyzed by Taqman quantitative real-time PCR (qPCR),
as described (6), using KLF9 (Hs00230918_m1) and 36B4
Taqman probes (Applied Biosystems, Foster City, CA). The
comparative Ct method was used to quantify transcripts and
normalize to 36B4 expression levels, which did not vary with
ligand treatment.
Crystallographic modeling
Models of A263V or L274P mutant TRa1 were based on
structures of WT TRa1 (3ILZ) and generated using the
MacPyMOL Molecular Graphics System, v1.5.0.4 (Schro¨-
dinger, LLC, New York, NY).
Results
Clinical investigation
Patient P1 is of average proportionate height (50th centile;
subischial leg length +1 SD; Fig. 1A and Table 1). He has
mild macroglossia and slightly broad facies with a few skin
tags (Fig. 1B). His head circumference is increased (62.5 cm;
>99th centile); a skull radiograph showed a thickened cal-
varium (Fig. 2A) and delayed dentition (Fig. 2C). Abdominal
and pelvic imaging showed a loaded bowel (Fig. 2B) with
normal femoral epiphyses (Supplementary Fig. S1; Supple-
mentary Data are available online at www.liebertpub.com/
thy). Off treatment, his fT4 was low-normal but with a high
fT3, subnormal rT3, and normal skeletal muscle CK levels.
His resting energy expenditure was low-normal (Table 2).
Patient P2 has disproportionate short stature (height 0.4th
centile; normal sitting height with subischial leg length
-2 SD; Fig. 1D and Table 1). He has marked macroglossia
and is dysmorphic with broad facies, marked hypertelorism,
flat nasal bridge, puffy skin, and skin tags (Fig. 1C). His head
circumference is increased (60.5 cm; 99th centile); a skull
radiograph at four years of age showed multiple Wor-
mian bones (Fig. 2G), and his calvarium is now thickened
(Fig. 2D). Femoral epiphyseal dysgenesis seen in early
childhood (Fig. 2F) is no longer evident (Fig. 2E). Abdominal
imaging also showed a loaded bowel (Fig. 2E), and a spine
radiograph showed posterior scalloping of the lumbar ver-
tebrae (Fig. 2H). Prior to treatment, his fT4 was subnormal
with raised fT3 and low rT3 levels. Although his resting
energy expenditure was normal, muscle CK levels were
raised (Table 1).
Molecular genetic studies
THRA sequencing indicated that both patients were het-
erozygous for missense mutations (P1:c.788C>T, p.A263V;
P2:c.821T>C, p.L274P) involving both TRa1 and a2 pro-
teins. In both cases, the mutations occurred de novo, with
neither parent being affected. In each proband, the mutations
were present in DNA isolated from different cell types
(PBMCs, buccal epithelial tissue, hair follicle; Supplemen-
tary Figs. S2 and S3) and are not present in genome databases
(dBSNP, Exome Aggregation Consortium (ExAC), Cam-
bridge, MA; http://exac.broadinstitute.org, February 2017,
NHLBI exome server).
Functional properties of A263V and L274P
mutant TRa1 and a2 proteins
In functional assays, hormone-dependent transcriptional
activation by A263V mutant TRa1 is impaired at low T3
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Table 1. Comparison of Clinical and Biochemical Features in Patients
Phenotype Patient 1 (A263V) Patient 2 (L274P)
Age (years) 17 15
Skeletal Height (SDS) 50th centile 0.4th centilea
Subischial length +1 SD –2 SDa
Macrocephaly (SDS) 99th centile 99th centile
Femoral epiphyses Normal Dysgenesisb
Cranial hyperostosis + + and bWormian bones
Anterior fontanelle Closed Open
Bone age –2.7 SD –2 SD
Delayed dentition ++ ++
Appearance Macroglossia + ++
Broad facies + +++
Flat nasal bridge + +++
Skin tags + ++
Gastrointestinal Constipation + +++
Neurocognitive Delayed milestones + +++
Motor dyspraxia + ++
Dysarthria + ++
Cognitive function Regular school Special needs school
Biochemical T4 Low-normal Low
T3 High High
T4/T3 ratio Low Low
Reverse T3 Low Low
Creatine kinase Normal Raised
IGF-1 Normal Normal
Anemia Yes Yes
+ Indicates present, mild; ++ indicates present, moderate; +++ indicates present, severe/marked.
aPost T4 therapy.
bIn childhood.
T4, thyroxine; T3, triiodothyronine.
FIG. 1. Phenotypic char-
acteristics of patient P1
(A and B) and patient P2
(C and D), illustrating their
stature and facial features.
Photos used with permission.
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FIG. 2. Radiological abnormali-
ties in patients P1 and P2 illustrat-
ing thickened calvarium in P1 (A)
and P2 (D), loaded bowel in P1 (B)
and P2 (E), delayed dentition in P1
(C), femoral epiphyseal dysgenesis
(F), Wormian bones in P2 (early
childhood) (G), and scalloped pos-
terior lumbar vertebrae in P2 (H).
Table 2. Biochemical and Metabolic Measurements in Patients Off and On T4
THRA mutation P1 (A263V) P2 (L274P) Reference valuesa
Age (years) 17.1 18.5 15.55 15.7
T4 (lg/day) Nil 87.5 Nil 62.5 ..
Weight (kg) 85.8 78.2 47.5 49.4 ..
REE (MJ/kg lean
body mass/day)
0.134 0.112b 0.151 0.158 P1: n = 23; mean (range) REE 0.146
(0.102–0.179)
P2: n = 20; mean (range) REE 0.156
(0.131–0.184)
SHR (beats/min) 53 52 65 66 (P1: n = 23; mean (range)
SHR 53 (40–70)
(P2: n= 20; mean (range)
SHR 54.4 (40–70)
TSH (mIU/L) 3.6 0.09 2.07 <0.033 0.35–5.50
fT4 (pmol/L) 10 14.1 8.4 11.2 10.0–19.8
fT3 (pmol/L) 7.6 7.6 9.1 12.2 3.5–6.5
rT3 (nmol/L) <0.07 0.17 <0.07 0.08 0.12–0.36
CK (U/L) 136 120 213 200 47–163
IGF-1 (nmol/L) 44.4 52.7 35.5 28.7 15–64.8
SHBG (nmol/L) 22 29 39 42 P1: n = 10 age 15–16.9; mean (range)
SHBG 34 (18–46)
P2: n = 13 age 14.6–16.9; mean (range)
SHBG 34 (18–46)
Total cholesterol (mmol/L) 4.8 4.2 4.1 3.8 <5
LDL cholesterol (mmol/L) 2.9 2.4 2.2 2.0 <3
Hct l/L 0.35 0.35 0.40 0.35 0.37–0.49
aFor some parameters (resting energy expenditure, sleeping heart rate, SHBG), reference values (mean and range) from age- and sex-
matched healthy children are shown.
bAn interim REE measurement in P1, at 17.5 years of age on 75 lg T4 therapy, was 0.133MJ/kg lean body mass/day.
REE, resting energy expenditure; SHR, sleeping heart rate; TSH, thyrotropin; fT4, free T4; fT3, free T3; rT3, reverse T3; CK, creatine
kinase; SHBG, sex hormone binding globulin; LDL, low-density lipoprotein.
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concentrations (0.01–100 nM), but is comparable to WT re-
ceptor at higher T3 levels (1–10 lM). In contrast, L274P
mutant TRa1 exhibits negligible transcriptional activity ex-
cept at the highest T3 concentrations (10 lM; Fig. 3A).
Consistent with this, in protein–protein interaction assays,
A263Vmutant TRa1 dissociates from corepressor (CoR) and
recruits coactivator (CoA) at lower T3 concentrations (CoR
dissociation 100 nM; CoA recruitment 1 lM) than L274P
mutant TRa1 (maximal CoR dissociation and CoA recruit-
ment at 10 lM; Fig. 3C and D).
When coexpressed, mutant receptors inhibit the transcrip-
tional activity of their WT counterparts in a dominant nega-
tivemanner. Lower T3 levels (100 nM) reverse such dominant
negative inhibition by A263Vmutant TRa1 than inhibition by
L274P mutant TRa1 (10lM; Fig. 4A). Correlating with this,
reduced expression of a known TH-responsive target gene
(KLF9) is normalized by exposure of A263V mutant TRa1-
containing PBMCs to lower concentrations of T3 (1lM),with
L274P mutant TRa1-containing cells being refractory, even
with 10lM of T3 exposure (Fig. 4B).
When studied in the TRa2 background, the L274P mutant
a2 was transcriptionally inert, similar to WT a2 (Supple-
mentary Fig S4A). As with WT TRa2, it inhibited the func-
tion of WT TRa1, but only when coexpressed at 10- to 50-
fold higher levels (Supplementary Fig. S4B). These proper-
ties are wholly analogous to those of A263V mutant a2,
which have been reported previously (6).
Response to T4 therapy
T4 therapy for 18 months in patient P1 (A263V mutant
TRa), accompanied by an appropriate rise in fT4, fT3, and
FIG. 3. Functional properties of A263V and L274P mutant thyroid hormone receptor a1 (TRa1). (A) Triiodothyronine
(T3)-dependent activation assayed in JEG-3 cells transfected with empty, wild-type (WT), or A263V or L274P mutant
TRa1 expression vectors, together with a thyroid hormone–responsive target gene (mean + standard error of the mean
[SEM] of at least five independent experiments each in triplicate); the inset shows an EMSA with comparable interaction of
unliganded or hormone-bound WT/RXR or L274P/RXR or A263V/RXR heterodimers with a direct repeat thyroid response
element from the malic enzyme gene. (B) Western blotting confirming comparable expression of WT and mutant VP16-
receptor fusion proteins in protein–protein interaction assays. (C and D) Protein–protein interaction assays in JEG-3 cells
cotransfected with a reporter gene (UASTKLUC) constructs expressing a heterologous activation domain alone or linked to
TRs (VP16, VP16-WT, VP16-A263V, VP16-L274P) and vectors expressing either GAL4-NCoR (Panel C) or GAL4-
TRAP220 fusion proteins (D) (mean + SEM of at least five independent experiments each in triplicate).
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FIG. 4. (A) Dominant negative inhibition was tested in cells cotransfected with reporter gene and equal combinations of
FLAG epitope-tagged expression vectors as indicated (mean + SEM of at least five independent experiments each in
triplicate), with receptor quantitation by Western blotting (inset). (B) Quantitative real-time PCR (internal control: 36B4,
acidic ribosomal phosphoprotein) showing expression of KLF9 in peripheral blood mononuclear cells from each patient
(A263V and L274P) or healthy controls with changing T3 concentrations.
FIG. 5. Charts showing height (left panel) or weight (right panel) standard deviation scores (normal range shaded), with
serial measurements in patients P1 (A263V mutant TRa) or P2 (L274P mutant TRa). Arrowed points denote com-
mencement of thyroxine treatment.
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rT3 levels (Table 2), was associated with improved linear
growth (Fig. 4, left panel) and striking reduction in weight
(Fig 4, right panel), largely due to diminished fat mass (pre-
treatment: total body fat mass 26,950 g, 31%; posttreatment:
total body fat mass 20,520 g, 23%). Significantly, such an
improvement in body composition was associated with ben-
eficial metabolic changes, with a reduction in fasting insulin
and a rise in circulating adiponectin levels (pretreatment: in-
sulin 156 pmol/L [reference range 0–60 pmol/L], adiponectin
3.4lg/mL; posttreatment: insulin 75 pmol/L, adiponectin
7.1lg/mL). In contrast, despite T4 treatment since 11 years of
age, achieving similar changes in thyroid hormone levels
(Table 2), patient P2 (L274P mutant TRa) exhibited negligi-
ble change in linear growth (Fig. 5 left panel) and ongoing
weight gain, which was only reversed when on a higher T4
dose (62.5lg) from 14 years of age (Fig. 5, right panel).
Following T4 treatment, resting energy expenditure was
either unchanged or reduced on one occasion in P1 or slightly
increased in P2, and sleeping heart rate was unchanged in
both patients. Muscle CK and serum cholesterol (total and
low-density lipoprotein) levels fell, with a slight rise in serum
sex hormone binding globulin in both cases. Subnormal he-
matocrit in both patients remained unchanged (Table 2).
After T4 therapy, patient P1 reported marked changes, in-
cluding better concentration and school performance, greater
motivation and social confidence, improved coordination, and
decreased constipation. Although patient P2 also reported greater
regularity of bowel habits on T4 therapy, his alertness, energy
levels, cool peripheries, and abnormal gait were unchanged.
Discussion
Two adolescent patients (P1 and P2) with THRAmutations
were studied, and it was found that in each case, their clinical
features and response to T4 therapy correlate with the func-
tional properties of underlying mutant TRa.
P1 (A263V mutant TRa), relatively asymptomatic and
diagnosed when investigated for possible delayed puberty,
was of proportionate stature, slightly dysmorphic, and with
mild neurocognitive impairment. In contrast, P2 (L274P
mutant TRa) was investigated extensively in childhood for
problems including neurodevelopmental delay and skeletal
dysplasia and is growth retarded, quite dysmorphic, and
markedly dyspraxic with cognitive deficit. Other features
(macrocephaly, delayed dentition and bone age, constipation,
and anemia) are common to both cases (Table 1).
FIG. 6. Crystal structure of the ligand binding domain of TRa1. The backbone of ligand (T3) is shown in blue with atoms
in different colors (purple: iodine; red: oxygen); selected amino acid side chains are shown, colored by atom type; the
location and sidechains of residues (Ala 263, Leu274) and the amino acids they are mutated to are shown in orange.
Hydrogen bonds are indicated by dashed red lines (PDBID 2H77). (A) The location of amino acids (Ala 263, Leu 274) that
are mutated in each patient is shown. (B) The side chain of alanine 263 makes a favorable van der Waals interaction with the
T3 ligand. (C) Mutation of alanine 263 to valine would create some steric hindrance to T3 binding. (D) Leucine 274 forms a
hydrophobic buttress with the side chains of isoleucine 299 and phenylalanine 300 in helix 8, enabling the delta methyl group
of isoleucine 299 to interact with T3 ligand. (E) The backbone of leucine 274 forms part of the hydrogen bonding network of
the two beta strands. (F) Mutation of leucine 274 to proline would clash sterically with the sidechain of phenylalanine 300,
perturbing the position of helix 8 and also disrupt hydrogen bonding within the beta sheet in which it is located.
980 MORAN ET AL.
In functional studies, A263V mutant TRa1 is transcrip-
tionally impaired and inhibits function of its WT counterpart
at low T3 levels (0.01–10 nM), but higher T3 concentrations
(>100 nM) reverse such dysfunction and dominant nega-
tive inhibition, both in cotransfection assays in vitro and
mutation-containing, patient-derived, PBMCs studied ex
vivo. In contrast, only very high T3 concentrations (10lM)
reverse dysfunction of L274P mutant TRa1 in vitro, with
failure to reverse subnormal KLF9 expression in patient’s
cells studied ex vivo. Structural modeling provides an ex-
planation for such divergence in properties. The steric clash
created by mutating alanine 263 to valine could be accom-
modated by slight repositioning of ligand (T3) (Fig. 6).
However, the effect of mutating leucine 274 to proline would
be much more dramatic because in the WT TRa1, the non-
polar side chain of leucine 274 forms a hydrophobic buttress
with the side chains of isoleucine 299 and phenylalanine 300
in helix 8, enabling the delta methyl group of isoleucine 299
to interact with T3 ligand. Substitution of proline for leucine
274 would no longer buttress isoleucine 299 weakening its
interaction with T3, clash sterically with the sidechain of phe-
nylalanine 300, perturbing the position of helix 8, and disrupt
hydrogen bonding within the beta sheet in which it is located,
perturbing normal interaction of leucine 276 and serine 277
with ligand (Fig. 6).
Differences in T3-dependent reversibility of mutant re-
ceptor dysfunction in vitro are also correlated with differ-
ential responses of patients to T4 therapy: P1 (A263V mutant
TRa) showed a change in linear growth, striking reduction in
weight (fat mass), and improved dyspraxia, educational
performance, and social engagement, whereas linear growth,
motor incoordination, and mental alertness were unchanged
in P2 (L274P mutant TRa), with reduction in weight only
after increase in T4 dose.
The receptor defects identified in these patients increase
the repertoire of RTHa-associated TRa mutations described
hitherto (10), enabling relationships between genotype and
phenotype to be further discerned. A mild phenotype in three
individuals with A263V mutant TRa was previously docu-
mented (6), but they had been treated with T4 since very early
childhood. However, mild clinical features in P1 who was not
treated with T4 until late adolescence and in seven members
of another family with a different amino acid change (A263S)
at this locus (9) suggest that the phenotype associated with
this mutant TRa genotype is intrinsically mild. It is also
noteworthy that both receptor mutations reported here oc-
curred de novo, such that 9 of the 14 TRamutations recorded
hitherto have occurred sporadically. As has been documented
in RTHb (11), this raises the possibility that more frequent
occurrence of changes in mutation-prone nucleotides will
result in certain codon changes being overrepresented in this
disorder.
The L274P TRa mutation in P2 has a counterpart, with an
amino acid change in the equivalent TRb residue (L328S) in
RTHb (12). Indeed, most RTHa-associated TRa mutations
described to date have an RTHb-associated TRb counterpart
(10), raising the possibility that RTHa-associated TRa mu-
tations will localize to particular regions within the receptor
protein, as has been documented in RTHb.
Although both the TRa mutations identified in the present
patients also involve the TRa2 isoform, no added phenotype
attributable to this could be discerned, and no gain or loss of
function could be documented with the introduction of these
amino acid changes into the TRa2 background. Thus, with
the exception of a single case in which unusual skeletal and
other features were recorded (7), no readily recognizable
additional phenotypes could be identified in 14 individuals
harboring mutations common to both TRa1 and TRa2 pro-
teins (6,8,9). However, the possibility cannot be discounted
of a mutation in TRa2 being associated with a phenotype that
is either so subtle or of variable penetrance that it can only be
discerned in a larger cohort of RTHa cases.
T4 therapy was permissive for increase in linear growth in
P1 and also had beneficial metabolic effects in both him and
three other individuals with the same TRa mutation (6):
marked improvement in hypotonia, motor skills, and growth
was recorded following T4 treatment at 18 months in an
infant with another T3-reversible TRamutation (D211G) (8).
In a murine model of RTHa, harboring a missense (R384C)
TRa1 mutation with T3-reversible dysfunction, raising cir-
culating TH levels even in adult life, alleviated locomotor
and behavioral abnormalities (13). Interestingly, as in patient
P2, constipation has been noted to improve, even in cases
with a highly deleterious TRa defect (3,4). Overall, these
observations suggest that a trial of T4 therapy is warranted in
RTHa with mild mutations, as has been advocated by others
(14), and that it could alleviate some symptoms, even in
patients with a severe receptor defect. However, as observed
in P1 and P2, suppression of TSH, fall in serum cholesterol,
and rise in sex hormone binding globulin levels after T4
therapy (4,6) do suggest thyromimetic effects in TRb-
expressing tissues (e.g., pituitary, liver), and the long-term
consequences of this are unknown. Perhaps this provides the
rationale for development of TRa-selective analogues that
are potentially devoid of such effects.
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